<DOC>
	<DOCNO>NCT01579019</DOCNO>
	<brief_summary>This randomize , double blind , phase II study evaluate efficacy safety two dos RO5024048 combination ritonavir-boosted danoprevir Pegasys ( peginterferon alpha-2a ) Copegus ( ribavirin ) patient fail prior protease inhibitor contain regimen without pegylated interferon . Patients randomize receive either 2-week lead-in RO5024048 ( 1500 mg 1000 mg orally twice daily ) combination Pegasys ( 180 mcg subcutaneously weekly ) Copegus ( 1000 mg 1200 mg orally daily ) follow 24 week therapy RO5024048 combination danoprevir ( 100 mg orally twice daily ) plus ritonavir ( 100 mg orally twice daily ) Pegasys Copegus ( QUAD therapy ) , 24 week therapy RO5024048 combination danoprevir plus ritonavir Pegasys Copegus ( QUAD therapy ) . Anticipated time study treatment 24 26 week , treatment-free follow-up 24 week .</brief_summary>
	<brief_title>A Study RO5024048 Combination With Ritonavir-Boosted Danoprevir Pegasys/Copegus Patients With Chronic Hepatitis C Genotype 1 Who Have Failed Prior HCV Protease Inhibitor Treatment</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Protease Inhibitors</mesh_term>
	<criteria>Adult patient , &gt; /= 18 year age Hepatitis C genotype 1 infection Serum HCV quantifiable Roche COBAS TaqMan HCV Test v2.0 Liver biopsy ( within 24 month ) Fibroscan ( within 12 month ) first administration study drug consistent chronic hepatitis C demonstrate absence liver cirrhosis Documented fail prior treatment protease inhibitor ( evidenced viral breakthrough partial response treatment relapse treatment ) , include documentation treatment directacting antiviral agent HCV antiviral treatment Patients must discontinue prior HCV treatment least 24 week prior first dose study drug trial Infection HCV genotype genotype 1 Evidence variant associated protease inhibitor resistance screen Body mass index ( BMI ) &lt; 18 &gt; /=36 kg/m2 Positive hepatitis A hepatitis B infection Use systemic antiviral therapy perceive activity HCV &lt; /=1 month prior first dose study drug History evidence medical condition associate chronic liver disease chronic hepatitis C Pregnant breastfeed woman Males female partner pregnant History immunologically mediate disease ; patient rheumatoid arthritis require intermittent nonsteroidal antiinflammatory medication celiac disease allow History evidence decompensated liver disease History evidence renal disease ; patient history nephrolithiasis allow Uncontrolled Type 1 2 diabetes History evidence chronic pulmonary disease associate functional limitation History severe cardiac disease History neoplastic disease within last 5 year , except localize situ carcinoma skin ( e.g . basal squamous cell carcinoma ) Evidence excessive alcohol , drug substance abuse ( exclude marijuana use ) within 1 year first dose study drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>